Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet

Oxaliplatin: A Novel Platinum Analog With Activity in Colorectal Cancer

Deborah Berg
ONF 2003, 30(6), 957-966 DOI: 10.1188/03.ONF.957-966

Purpose/Objectives: To review selected recent data pertaining to the use of oxaliplatin in colorectal cancer and its implications for oncology nursing.

Data Sources: Published articles, abstracts, and conference proceedings.

Data Synthesis: Colorectal cancer accounts for about 15% of all new cancers. The search for more effective chemotherapy regimens is ongoing. Oxaliplatin, a member of the diaminocyclohexane family of platinum compounds, demonstrates cytotoxic efficacy and a well-tolerated safety profile.

Conclusions: Oxaliplatin is effective in chemotherapy-naive patients with advanced colorectal cancer, as well as in those refractory to previous treatment with 5-fluorouracil (5-FU); the drug also is effective in combination with 5-FU and leucovorin for the treatment of advanced colorectal cancer.

Implications for Nursing: Nurses must be highly knowledgeable about oxaliplatin regimens and schedules, the associated side effects, and recommended strategies for symptom management. This article can help nurses to understand and communicate the benefits and risks associated with oxaliplatin-based therapies to colleagues and patients.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or